Free Trial
NASDAQ:ELAB

PMGC (ELAB) Stock Price, News & Analysis

PMGC logo
$2.14 -0.03 (-1.38%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$2.13 -0.01 (-0.51%)
As of 06/27/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PMGC Stock (NASDAQ:ELAB)

Key Stats

Today's Range
$2.11
$2.17
50-Day Range
$2.04
$2.91
52-Week Range
$1.95
$839.86
Volume
36,948 shs
Average Volume
382,214 shs
Market Capitalization
$2.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

PMGC Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

ELAB MarketRank™: 

PMGC scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for PMGC.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PMGC is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PMGC is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    PMGC has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about PMGC's valuation and earnings.
  • Percentage of Shares Shorted

    16.16% of the float of PMGC has been sold short.
  • Short Interest Ratio / Days to Cover

    PMGC has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PMGC has recently increased by 217.39%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    PMGC does not currently pay a dividend.

  • Dividend Growth

    PMGC does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.16% of the float of PMGC has been sold short.
  • Short Interest Ratio / Days to Cover

    PMGC has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PMGC has recently increased by 217.39%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    PMGC has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Multi-Sector Conglomerates companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for PMGC this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, PMGC insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.60% of the stock of PMGC is held by insiders.

  • Percentage Held by Institutions

    Only 22.22% of the stock of PMGC is held by institutions.

  • Read more about PMGC's insider trading history.
Receive ELAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PMGC and its competitors with MarketBeat's FREE daily newsletter.

ELAB Stock News Headlines

PMGC Holdings Inc News (ELAB) - Investing.com
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
PMGC (NASDAQ:ELAB) Trading 2.9% Higher - What's Next?
See More Headlines

ELAB Stock Analysis - Frequently Asked Questions

PMGC's stock was trading at $16.03 at the start of the year. Since then, ELAB stock has decreased by 86.7% and is now trading at $2.14.
View the best growth stocks for 2025 here
.

PMGC Holdings Inc. (NASDAQ:ELAB) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($2.90) EPS for the quarter. PMGC had a negative trailing twelve-month return on equity of 77.80% and a negative net margin of 223.41%.

PMGC's stock reverse split on Monday, March 10th 2025.A 1-7 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, March 9th 2025. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

PMGC (ELAB) raised $6 million in an initial public offering on Tuesday, November 21st 2023. The company issued 1,500,000 shares at $4.00 per share. Univest Securities served as the underwriter for the IPO.

Shares of ELAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PMGC investors own include BIOLASE (BIOL), Conduit Pharmaceuticals (CDT), Cyclacel Pharmaceuticals (CYCC), Dare Bioscience (DARE), TRACON Pharmaceuticals (TCON), Tempest Therapeutics (TPST) and 22nd Century Group (XXII).

Company Calendar

Last Earnings
5/14/2025
Today
6/28/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
DIVERSIFIED OPS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELAB
Previous Symbol
NASDAQ:ELAB
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.25 million
Net Margins
-223.41%
Pretax Margin
-505,406.53%

Debt

Sales & Book Value

Annual Sales
$1.71 million
Price / Cash Flow
N/A
Book Value
$11.53 per share
Price / Book
0.19

Miscellaneous

Free Float
1,367,000
Market Cap
$2.95 million
Optionable
N/A
Beta
-0.37
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:ELAB) was last updated on 6/29/2025 by MarketBeat.com Staff
From Our Partners